US3705185A
(en)
|
1969-04-14 |
1972-12-05 |
Minnesota Mining & Mfg |
N-aroyl sulfonamides
|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
US4130566A
(en)
|
1977-10-27 |
1978-12-19 |
Sumitomo Chemical Company, Limited |
Process for producing 5-carboxy-2-acetylthiophene
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
EP0102324A3
(fr)
|
1982-07-29 |
1984-11-07 |
Ciba-Geigy Ag |
Lipides et composés tensio-actifs en phase aqueuse
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
GB8524157D0
(en)
|
1984-10-19 |
1985-11-06 |
Ici America Inc |
Heterocyclic amides
|
US5004697A
(en)
|
1987-08-17 |
1991-04-02 |
Univ. Of Ca |
Cationized antibodies for delivery through the blood-brain barrier
|
DK24089D0
(da)
|
1989-01-20 |
1989-01-20 |
Hans Bundgaard |
Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups
|
GB8911854D0
(en)
|
1989-05-23 |
1989-07-12 |
Ici Plc |
Heterocyclic compounds
|
US5268164A
(en)
|
1990-04-23 |
1993-12-07 |
Alkermes, Inc. |
Increasing blood-brain barrier permeability with permeabilizer peptides
|
US5112596A
(en)
|
1990-04-23 |
1992-05-12 |
Alkermes, Inc. |
Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
|
AU1625192A
(en)
|
1991-05-31 |
1992-12-03 |
Zeneca Limited |
Heterocyclic derivatives
|
AU677216B2
(en)
|
1992-07-27 |
1997-04-17 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Targeting of liposomes to the blood-brain barrier
|
DK0669920T3
(da)
|
1992-11-23 |
2003-05-26 |
Aventis Pharma Inc |
Substituerede 3-(aminoalkylamino)-1,2-benzisoxazoler og beslægtede forbindelser
|
US5573653A
(en)
|
1994-07-11 |
1996-11-12 |
Sandoz Ltd. |
Electrochemical process for thiocyanating aminobenzene compounds
|
CA2198457A1
(fr)
|
1994-08-30 |
1996-03-07 |
Koichi Kojima |
Derives d'isoxazole
|
US5753653A
(en)
|
1995-12-08 |
1998-05-19 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
|
GB9828442D0
(en)
|
1998-12-24 |
1999-02-17 |
Karobio Ab |
Novel thyroid receptor ligands and method II
|
US6514221B2
(en)
|
2000-07-27 |
2003-02-04 |
Brigham And Women's Hospital, Inc. |
Blood-brain barrier opening
|
WO2002017930A2
(fr)
|
2000-08-30 |
2002-03-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Agents bloquants des glucocorticoides pour augmenter la permeabilite de la barriere hemato-encephalique
|
US7034036B2
(en)
|
2000-10-30 |
2006-04-25 |
Pain Therapeutics, Inc. |
Inhibitors of ABC drug transporters at the blood-brain barrier
|
DE10121982B4
(de)
|
2001-05-05 |
2008-01-24 |
Lts Lohmann Therapie-Systeme Ag |
Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
|
AU2002322720B2
(en)
|
2001-07-25 |
2008-11-13 |
Raptor Pharmaceutical Inc. |
Compositions and methods for modulating blood-brain barrier transport
|
KR100789567B1
(ko)
|
2001-11-06 |
2007-12-28 |
동화약품공업주식회사 |
3-아미도-1,2-벤조이소옥사졸 유도체, 그 염, 제조방법 및 용도
|
DE10201550A1
(de)
|
2002-01-17 |
2003-07-31 |
Merck Patent Gmbh |
Phenoxy-Piperidine
|
US20030162695A1
(en)
|
2002-02-27 |
2003-08-28 |
Schatzberg Alan F. |
Glucocorticoid blocking agents for increasing blood-brain barrier permeability
|
AU2003264017B2
(en)
|
2002-08-08 |
2010-05-27 |
Memory Pharmaceuticals Corporation |
Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors
|
KR101111477B1
(ko)
|
2002-12-03 |
2012-02-23 |
블랜체트 록펠러 뉴로사이언시즈 인스티튜트 |
치료제와 연결된 콜레스테롤을 포함하는 접합체
|
MY141521A
(en)
|
2002-12-12 |
2010-05-14 |
Hoffmann La Roche |
5-substituted-six-membered heteroaromatic glucokinase activators
|
JP2006523671A
(ja)
|
2003-04-15 |
2006-10-19 |
ファイザー・インク |
PPAR調節剤としてのα置換カルボン酸
|
CN101643458A
(zh)
|
2003-08-08 |
2010-02-10 |
沃泰克斯药物股份有限公司 |
在疼痛的治疗中用作钠或钙通道阻断剂的杂芳基氨基磺酰基苯基衍生物
|
WO2005013914A2
(fr)
|
2003-08-08 |
2005-02-17 |
Vertex Pharmaceuticals Incorporated |
Compositions utilisees comme inhibiteurs de canaux sodium voltage dependants
|
EP1663239A4
(fr)
|
2003-09-10 |
2008-07-23 |
Cedars Sinai Medical Center |
Administration assistee par les canaux potassiques d'agents a travers la barriere hemato-encephalique
|
MXPA06003618A
(es)
|
2003-10-03 |
2006-08-11 |
Portola Pharm Inc |
2, 4-dioxo-3-quinazolinilaril sulfonilureas.
|
US7081539B2
(en)
|
2004-03-25 |
2006-07-25 |
Dainippon Sumitomo Pharma Co., Ltd. |
One-pot process for the preparation of 1,2-benzisoxazole-3-methanesulfonamide
|
CA2574971A1
(fr)
|
2004-07-30 |
2006-02-09 |
Merck & Co., Inc. |
Facteurs de potentialisation d'indanone de recepteurs metabotropiques de glutamates
|
AU2005272786B2
(en)
|
2004-08-12 |
2011-12-22 |
Amgen Inc. |
Bisaryl-sulfonamides
|
NZ554211A
(en)
|
2004-09-29 |
2010-10-29 |
Portola Pharm Inc |
Substituted 2H-1,3-Benzoxazin-4(3H)-ones
|
JP2008189549A
(ja)
|
2005-05-12 |
2008-08-21 |
Astellas Pharma Inc |
カルボン酸誘導体またはその塩
|
DE102005038947A1
(de)
|
2005-05-18 |
2006-11-30 |
Grünenthal GmbH |
Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
|
US7632837B2
(en)
|
2005-06-17 |
2009-12-15 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid-1 receptor modulators
|
WO2007030582A2
(fr)
|
2005-09-09 |
2007-03-15 |
Bristol-Myers Squibb Company |
Inhibiteurs d'ikur acycliques
|
ATE425138T1
(de)
|
2005-10-19 |
2009-03-15 |
Hoffmann La Roche |
N-phenyl-phenylacetamid-nichtnukleosidinhibitor n reverser transkriptase
|
WO2007062078A2
(fr)
|
2005-11-23 |
2007-05-31 |
Ligand Pharmaceuticals Inc. |
Composes modulant l'activite thrombopoietine et procedes correspondants
|
AR058296A1
(es)
|
2005-12-09 |
2008-01-30 |
Kalypsys Inc |
Inhibidores de histona desacetilasa y composicion farmaceutica
|
CN101466665B
(zh)
|
2006-04-11 |
2013-12-04 |
沃泰克斯药物股份有限公司 |
适用作电压-门控钠通道抑制剂的组合物
|
ATE542818T1
(de)
|
2006-10-11 |
2012-02-15 |
Amgen Inc |
Imidazo- und triazolopyridinverbindungen und verfahren zu deren anwendung
|
US20110281821A9
(en)
|
2007-01-30 |
2011-11-17 |
Biogen Idec Ma Inc. |
Modulators of Mitotic Kinases
|
CA2677493A1
(fr)
|
2007-02-05 |
2008-08-14 |
Xenon Pharmaceuticals Inc. |
Composes de pyridopyrimidinone utiles dans le traitement de maladies ou d'affections vehiculees par les canaux sodiques
|
WO2008118758A1
(fr)
|
2007-03-23 |
2008-10-02 |
Icagen, Inc. |
Inhibiteurs de canaux ioniques
|
AU2008256937A1
(en)
|
2007-05-25 |
2008-12-04 |
Vertex Pharmaceuticals Incorporated |
Ion channel modulators and methods of use
|
MX2009013355A
(es)
|
2007-06-07 |
2010-02-22 |
Astellas Pharma Inc |
Compuesto de piridona.
|
US20090012103A1
(en)
|
2007-07-05 |
2009-01-08 |
Matthew Abelman |
Substituted heterocyclic compounds
|
TW200911766A
(en)
|
2007-07-13 |
2009-03-16 |
Astrazeneca Ab |
New compounds
|
US8124610B2
(en)
|
2007-07-13 |
2012-02-28 |
Icagen Inc. |
Sodium channel inhibitors
|
JPWO2009022731A1
(ja)
|
2007-08-10 |
2010-11-18 |
日本ケミファ株式会社 |
P2x4受容体拮抗剤
|
GB0720390D0
(en)
|
2007-10-18 |
2007-11-28 |
Prosidion Ltd |
G-Protein coupled receptor agonists
|
WO2009086303A2
(fr)
|
2007-12-21 |
2009-07-09 |
University Of Rochester |
Procédé permettant de modifier la durée de vie d'organismes eucaryotes
|
CA2728511A1
(fr)
|
2008-06-23 |
2009-12-30 |
Astellas Pharma Inc. |
Compose de sulfonamide ou sel de celui-ci
|
WO2010022055A2
(fr)
|
2008-08-20 |
2010-02-25 |
Amgen Inc. |
Inhibiteurs de canaux sodiques sensibles au potentiel
|
DK2385938T3
(en)
|
2009-01-12 |
2015-04-27 |
Pfizer Ltd |
Sulfonamidderivater
|
HUE034911T2
(hu)
|
2009-07-27 |
2018-03-28 |
Gilead Sciences Inc |
Fúzionált heterociklusos vegyületek mint ioncsatorna modulátorok
|
US8809380B2
(en)
|
2009-08-04 |
2014-08-19 |
Raqualia Pharma Inc. |
Picolinamide derivatives as TTX-S blockers
|
AU2010299114A1
(en)
|
2009-09-25 |
2012-04-12 |
Astellas Pharma Inc. |
Substituted amide compound
|
WO2011059042A1
(fr)
|
2009-11-12 |
2011-05-19 |
武田薬品工業株式会社 |
Composé cyclique aromatique
|
US8471034B2
(en)
|
2009-11-18 |
2013-06-25 |
Concert Pharmaceuticals, Inc. |
Niacin prodrugs and deuterated versions thereof
|
TW201139406A
(en)
|
2010-01-14 |
2011-11-16 |
Glaxo Group Ltd |
Voltage-gated sodium channel blockers
|
DK2533638T3
(en)
|
2010-02-12 |
2016-04-25 |
Nivalis Therapeutics Inc |
NOVEL S-nitrosoglutathione REDUCTASE
|
WO2011153588A1
(fr)
|
2010-06-10 |
2011-12-15 |
Biota Scientific Management Pty Ltd |
Inhibiteurs de polymérase virale
|
US20120004714A1
(en)
|
2010-06-30 |
2012-01-05 |
Ryan Kleve |
Lead having coil electrode with preferential bending region
|
US9279003B2
(en)
|
2010-07-07 |
2016-03-08 |
Purdue Pharma L.P. |
Analogs of sodium channel peptide toxin
|
ES2526675T3
(es)
|
2010-07-09 |
2015-01-14 |
Pfizer Limited |
N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
|
US9145407B2
(en)
|
2010-07-09 |
2015-09-29 |
Pfizer Limited |
Sulfonamide compounds
|
JP5830534B2
(ja)
|
2010-07-09 |
2015-12-09 |
ファイザー・リミテッドPfizer Limited |
化合物
|
CA2801032A1
(fr)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Derives de n-sulfonylbenzamide utiles comme inhibiteurs du canal sodique voltage-dependant
|
ES2526541T3
(es)
|
2010-07-12 |
2015-01-13 |
Pfizer Limited |
N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
|
JP2013536165A
(ja)
|
2010-07-12 |
2013-09-19 |
ファイザー・リミテッド |
痛みの処置のためのnav1.7阻害薬としてのスルホンアミド誘導体
|
CA2804716A1
(fr)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Composes chimiques
|
EP2593431B1
(fr)
|
2010-07-12 |
2014-11-19 |
Pfizer Limited |
N-sulfonylbenzamides comme inhibiteurs des canaux sodiques voltage-dépendant
|
US9120752B2
(en)
|
2010-07-16 |
2015-09-01 |
Purdue Pharma, L.P. |
Pyridine compounds as sodium channel blockers
|
SG188438A1
(en)
|
2010-09-13 |
2013-05-31 |
Novartis Ag |
Triazine-oxadiazoles
|
WO2012039657A1
(fr)
|
2010-09-22 |
2012-03-29 |
Astrazeneca Ab |
Composé chromane inédit pouvant être utilisé dans le cadre du traitement de la douleur
|
ES2570784T3
(es)
|
2010-12-22 |
2016-05-20 |
Purdue Pharma Lp |
Piridinas sustituidas como bloqueadores de los canales de sodio
|
WO2012095781A1
(fr)
*
|
2011-01-13 |
2012-07-19 |
Pfizer Limited |
Dérivés d'indazole comme inhibiteurs des canaux sodiques
|
AU2012212196B2
(en)
|
2011-02-02 |
2016-10-13 |
Vertex Pharmaceuticals Incorporated |
Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
|
MX347913B
(es)
|
2011-03-25 |
2017-05-17 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Ciclopropilaminas como inhibidores de desmetilasa 1 especifica de lisina.
|
EP2744805A1
(fr)
|
2011-08-17 |
2014-06-25 |
Amgen Inc. |
Inhibiteurs de canal sodium hétéroaryle
|
EP2766018A4
(fr)
|
2011-10-13 |
2015-02-25 |
Univ Case Western Reserve |
Composés agonistes de rxr et procédés associés
|
IN2014CN02959A
(fr)
|
2011-10-28 |
2015-07-03 |
Merck Sharp & Dohme |
|
JP6014155B2
(ja)
|
2011-10-31 |
2016-10-25 |
ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. |
ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
|
KR20140091022A
(ko)
|
2011-10-31 |
2014-07-18 |
제논 파마슈티칼스 인크. |
벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
|
WO2013072758A1
(fr)
|
2011-11-15 |
2013-05-23 |
Purdue Pharma L.P. |
Pyrimidine diol amides comme bloqueurs des canaux sodiques
|
WO2013086229A1
(fr)
|
2011-12-07 |
2013-06-13 |
Amgen Inc. |
Inhibiteurs aryle et hétéroaryle bicycliques des canaux calciques
|
JP6058023B2
(ja)
|
2011-12-15 |
2017-01-11 |
ファイザー・リミテッドPfizer Limited |
スルホンアミド誘導体
|
US20150291514A1
(en)
|
2012-01-04 |
2015-10-15 |
Pfizer Limted |
N-Aminosulfonyl Benzamides
|
JP2015083542A
(ja)
|
2012-02-08 |
2015-04-30 |
大日本住友製薬株式会社 |
3位置換プロリン誘導体
|
US8889741B2
(en)
|
2012-02-09 |
2014-11-18 |
Daiichi Sankyo Company, Limited |
Cycloalkane derivatives
|
WO2013122897A1
(fr)
|
2012-02-13 |
2013-08-22 |
Amgen Inc. |
Inhibiteurs des canaux sodiques de type dihydrobenzoxazine et tétrahydroquinoxaline
|
WO2013134518A1
(fr)
|
2012-03-09 |
2013-09-12 |
Amgen Inc. |
Inhibiteurs sulfamides des canaux de sodium
|
WO2013146969A1
(fr)
|
2012-03-29 |
2013-10-03 |
第一三共株式会社 |
Nouveau dérivé de cyclohexane disubstitué
|
MX2014014234A
(es)
|
2012-05-22 |
2015-05-07 |
Genentech Inc |
Benzamidas n-sustituidas y su uso en el tratamiento del dolor.
|
CA2878478A1
(fr)
|
2012-07-06 |
2014-01-09 |
Genentech, Inc. |
Benzamides n-substitues et leurs procedes d'utilisation
|
EP2876105A4
(fr)
|
2012-07-19 |
2016-01-13 |
Sumitomo Dainippon Pharma Co Ltd |
Dérivé de 1-(cycloalkyl-carbonyl)proline
|
CN104869992A
(zh)
|
2012-10-26 |
2015-08-26 |
默沙东公司 |
具有电压门控性钠通道选择性活性的n-取代的吲唑磺酰胺化合物
|
WO2014066490A1
(fr)
|
2012-10-26 |
2014-05-01 |
Merck Sharp & Dohme Corp. |
Composés benzoxazolinone ayant une activité sélective dans les canaux sodiques potentiel-dépendants
|
WO2014096941A1
(fr)
|
2012-12-20 |
2014-06-26 |
Purdue Pharma L.P. |
Sulfonamides cycliques en tant que bloquants des canaux sodiques
|
US9810473B2
(en)
|
2012-12-21 |
2017-11-07 |
Blue Quench Llc |
Modular retrofit quench unit
|
CN105026373B
(zh)
|
2013-01-31 |
2018-03-30 |
沃泰克斯药物股份有限公司 |
作为钠通道调节剂的吡啶酮酰胺
|
US20140296266A1
(en)
|
2013-03-01 |
2014-10-02 |
Gilead Sciences, Inc. |
Therapeutic compounds
|
WO2014153037A1
(fr)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Triazolopyridines substituées et leurs procédés d'utilisation
|
RU2015143834A
(ru)
|
2013-03-15 |
2017-04-24 |
Дженентек, Инк. |
Замещенные бензоксазолы и способы их применения
|
JP6449845B2
(ja)
|
2013-03-15 |
2019-01-09 |
クロモセル コーポレイション |
疼痛の処置のためのナトリウムチャネルモジュレーター
|
US9663508B2
(en)
|
2013-10-01 |
2017-05-30 |
Amgen Inc. |
Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
|
EP3074377B1
(fr)
|
2013-11-27 |
2018-10-17 |
Genentech, Inc. |
Benzamides substitués et leurs méthodes d'utilisation
|
CN106715418A
(zh)
|
2014-07-07 |
2017-05-24 |
基因泰克公司 |
治疗化合物及其使用方法
|
WO2016021742A1
(fr)
|
2014-08-07 |
2016-02-11 |
Takeda Pharmaceutical Company Limited |
Composés hétérocycliques utilisés en tant qu'antagonistes des récepteurs ccr4
|
JP2018526371A
(ja)
|
2015-08-27 |
2018-09-13 |
ジェネンテック, インコーポレイテッド |
治療化合物及びその使用方法
|
SG11201903348UA
(en)
|
2016-10-17 |
2019-05-30 |
Genentech Inc |
Therapeutic compounds and methods of use thereof
|